Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Aequus Pharmaceuticals Inc. (V:AQS)

Business Focus: Pharmaceuticals (NEC)

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for AQS within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Nov 29, 2023 18:05 ET
Aequus Reports Third Quarter 2023 Financial Highlights and General Update
Vancouver, BC - TheNewswire - November 29, 2023 - Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTC:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today reports financial results for the quarter ended September 30, 2023 (“Third Quarter 2023”) and associated Company developments. Unless otherwise noted, all figures are in Canadian currency.
Read full article
Oct 20, 2023 14:53 ET
Aequus Announces New Financing
Vancouver, BC - TheNewswire - October 20, 2023 - Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTC: AQSZF) (“Aequus” or the “Company”), announces today it has increased its debt by $1,000,000 to support operating costs and the new sales of Zimed® PF.  Mr. Doug Janzen, Chairman and Chief Executive Officer of the Company, has agreed to provide financing to Aequus by way of advanced funds on the same general conditions as previous advances, which is on demand with an interest rate of five percent (5%).
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.43
--
--
Price to Sales - TTM
3.39
3.85
3.46
Price to Book - most recent quarter
--
2.75
2.02
Price to Cash Flow per share - TTM
--
7.41
9.70
Price to Free Cash Flow per share - TTM
--
19.71
12.33
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Feb 29, 2024135-692
Feb 15, 2024827572
Jan 31, 2024255-8,756
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company focused on developing, advancing, and promoting differentiated products. The Company is engaged in the sale and marketing of several commercial products in ophthalmology and transplant. Its pipeline products include Evolve Intensive Gel, Evolve Daily Intensive, SCOPE Portfolio, Zimed PF and REV-0100 / ReVision. Evolve Intensive Gel and Evolve Daily Intensive contains lubricating eye drops intended for use in the relief of discomfort that arises from dry eye sensations, including dryness, soreness, feelings of grit, and irritation. Zimed PF is a preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. It plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license.

See business summary

 

Twitter

Search (past week) for $AQS.CA AQS.V

  • No tweets found